A representative from the Canadian Medical Association sent me--I don't know what it is--a paper, purportedly by them, in which they talk about a number of topics, one of them being strengthening post-marketing surveillance. I have no idea the date of this. It was faxed to me on January 23, 2008. This is what they say:
Currently post-marketing surveillance of drugs in Canada is inadequate, relying on reporting which is often erratic and inconsistent, and for which reporters are not compensated. Canada needs a coordinated post-marketing surveillance system to monitor the ongoing safety of marketed drugs. Surveillance should include medication incidents and adverse drug reactions, and should document and consider the effect of the “systems factors” contributing to these events.
Of course, I don't want you to repeat what you've spent the last two hours talking about, but have you got anything to add to this? I assume they're going to come. I assume this is a reliable piece of paper I have and that it's accurate, so if they're going to come, they're going to say this.